Abstract | BACKGROUND: The goal of the current study was to evaluate the objective response rate and toxicity associated with the oral fluoropyrimidine S-1 (a combination of tegafur, 5-chloro-2,4-dihydroxypyridine, and potassium oxonate) in patients with previously untreated metastatic colorectal carcinoma. METHODS: Thirty-eight patients were enrolled in the study. S-1 was administered orally at a dose of 40 mg/m2 twice daily for 28 days, followed by a 14-day rest period. Treatment was repeated every 6 weeks unless disease progression was observed. RESULTS: A combined total of 173 courses of S-1 were administered to the 38 enrolled patients. The median number of courses administered to a given patient was 3.5 (range, 1-18). Although no patient exhibited a complete response to treatment, 15 had partial responses (response rate, 39.5%; 95% confidence interval, 24.0-56.6%). In addition, 5 patients had minor responses, and 14 had stable disease. Four patients were found to have progressive disease after two courses of treatment. The median survival time was 358 days (95% confidence interval, 305-490 days), and the 1-year survival rate was 47.4%. The most common adverse reactions included myelosuppression and gastrointestinal toxicity; most cases involved Grade 1 or 2 toxicity, but Grade 3 toxicities ( anemia [7.9% of patients], neutropenia [5.3% of patients], diarrhea [2.6% of patients], and abnormal bilirubin levels [7.9% of patients]) also were noted. Neither Grade 4 toxicity nor treatment-related death was observed during the study. CONCLUSIONS: Orally administered S-1 is active against metastatic colorectal carcinoma and has an acceptable toxicity profile. This promising agent has the potential to become a valuable chemotherapeutic option.
|
Authors | Kuniaki Shirao, Atsushi Ohtsu, Hideho Takada, Yasushi Mitachi, Kosei Hirakawa, Noboru Horikoshi, Takeshi Okamura, Koichi Hirata, Soh Saitoh, Hiroharu Isomoto, Atsushi Satoh |
Journal | Cancer
(Cancer)
Vol. 100
Issue 11
Pg. 2355-61
(Jun 01 2004)
ISSN: 0008-543X [Print] United States |
PMID | 15160338
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2004 American Cancer Society. |
Chemical References |
- Antimetabolites, Antineoplastic
- Drug Combinations
- Pyridines
- S 1 (combination)
- Tegafur
- Oxonic Acid
|
Topics |
- Adenocarcinoma
(drug therapy, secondary)
- Administration, Oral
- Adult
- Aged
- Antimetabolites, Antineoplastic
(therapeutic use)
- Colorectal Neoplasms
(drug therapy, pathology)
- Drug Combinations
- Female
- Humans
- Male
- Middle Aged
- Oxonic Acid
(therapeutic use)
- Pyridines
(therapeutic use)
- Survival Rate
- Tegafur
(therapeutic use)
- Treatment Outcome
|